{"id":123743,"date":"2026-06-22T14:07:20","date_gmt":"2026-06-22T08:37:20","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=123743"},"modified":"2026-06-22T14:07:21","modified_gmt":"2026-06-22T08:37:21","slug":"cohance-lifesciences-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/","title":{"rendered":"Cohance Lifesciences Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Cohance Lifesciences share price target 2026 is Rs 495, implying approximately 20 percent upside from the current market price of Rs 414 (NSE: COHANCE). With Q4 FY26 results released in 2026 and Pharmaceutical CDMO and Contract Manufacturing tailwinds in focus, the Rs 495 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/cohance\/suven-pharmaceuticals-ltd-share-price-today\">Cohance Lifesciences<\/a> (NSE: COHANCE) is a Pharmaceutical CDMO and Contract Manufacturing company trading at Rs 414 with a market capitalisation of Rs 4,140 crore. Analysts have set the <strong>Cohance Lifesciences share price target<\/strong> at Rs 495 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Cohance_Lifesciences_Share_Price_Target_2026_Key_Takeaways\" title=\"Cohance Lifesciences Share Price Target 2026: Key Takeaways\">Cohance Lifesciences Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Cohance_Lifesciences_Company_Overview\" title=\"Cohance Lifesciences Company Overview\">Cohance Lifesciences Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Why_Is_the_Cohance_Lifesciences_Share_Price_Target_Set_at_Rs_495_for_2026\" title=\"Why Is the Cohance Lifesciences Share Price Target Set at Rs 495 for 2026\">Why Is the Cohance Lifesciences Share Price Target Set at Rs 495 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Pharmaceutical_CDMO_and_Contract_Manufacturing\" title=\"Structural Sector Tailwinds in Pharmaceutical CDMO and Contract Manufacturing\">Structural Sector Tailwinds in Pharmaceutical CDMO and Contract Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Cohance_Lifesciences_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Cohance Lifesciences Share Price Targets: Short Term, 12 Month, and Long Term\">Cohance Lifesciences Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Short_Term_Cohance_Lifesciences_Share_Price_Target\" title=\"Short Term Cohance Lifesciences Share Price Target\">Short Term Cohance Lifesciences Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#12-Month_Cohance_Lifesciences_Share_Price_Target_2026\" title=\"12-Month Cohance Lifesciences Share Price Target 2026\">12-Month Cohance Lifesciences Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Long_Term_Cohance_Lifesciences_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Cohance Lifesciences Share Price Target: FY27 to FY28\">Long Term Cohance Lifesciences Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_Cohance_Lifesciences_in_2026\" title=\"Bull Case and Bear Case Scenarios for Cohance Lifesciences in 2026\">Bull Case and Bear Case Scenarios for Cohance Lifesciences in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Bull_Case_Cohance_Lifesciences_Share_Price_Target_Rs_600\" title=\"Bull Case Cohance Lifesciences Share Price Target: Rs 600\">Bull Case Cohance Lifesciences Share Price Target: Rs 600<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Bear_Case_Cohance_Lifesciences_Share_Price_Target_Rs_330\" title=\"Bear Case Cohance Lifesciences Share Price Target: Rs 330\">Bear Case Cohance Lifesciences Share Price Target: Rs 330<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_Cohance_Lifesciences_2026_Price_Objective\" title=\"Key Risks That Could Derail the Cohance Lifesciences 2026 Price Objective\">Key Risks That Could Derail the Cohance Lifesciences 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Competitive_Intensity_Among_Pharmaceutical_CDMO_and_Contract_Manufacturing_Peers\" title=\"Competitive Intensity Among Pharmaceutical CDMO and Contract Manufacturing Peers\">Competitive Intensity Among Pharmaceutical CDMO and Contract Manufacturing Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#How_to_Invest_in_Cohance_Lifesciences\" title=\"How to Invest in Cohance Lifesciences\">How to Invest in Cohance Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#FAQs_on_Cohance_Lifesciences_Share_Price_Target_2026\" title=\"FAQs on Cohance Lifesciences Share Price Target 2026\">FAQs on Cohance Lifesciences Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_is_the_Cohance_Lifesciences_share_price_target_for_2026\" title=\"What is the Cohance Lifesciences share price target for 2026?\">What is the Cohance Lifesciences share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_was_the_Cohance_Lifesciences_share_price_target_for_2025\" title=\"What was the Cohance Lifesciences share price target for 2025?\">What was the Cohance Lifesciences share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#Is_Cohance_Lifesciences_a_good_investment_at_Rs_414\" title=\"Is Cohance Lifesciences a good investment at Rs 414?\">Is Cohance Lifesciences a good investment at Rs 414?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_are_the_key_risks_to_the_Cohance_Lifesciences_share_price_target_2026\" title=\"What are the key risks to the Cohance Lifesciences share price target 2026?\">What are the key risks to the Cohance Lifesciences share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Cohance_Lifesciences\" title=\"What is the 52 week high and low of Cohance Lifesciences?\">What is the 52 week high and low of Cohance Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_Cohance_Lifesciences_in_2026\" title=\"What are the main growth catalysts for Cohance Lifesciences in 2026?\">What are the main growth catalysts for Cohance Lifesciences in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#How_does_Cohance_Lifesciences_compare_to_its_peers\" title=\"How does Cohance Lifesciences compare to its peers?\">How does Cohance Lifesciences compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/cohance-lifesciences-share-price-target-2026\/#What_is_the_Cohance_Lifesciences_share_price_target_for_2027\" title=\"What is the Cohance Lifesciences share price target for 2027?\">What is the Cohance Lifesciences share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Cohance_Lifesciences_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Cohance Lifesciences Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Cohance Lifesciences share price target 2026:<\/strong> Rs 495 (20% upside from CMP Rs 414)<\/li>\n<li><strong>Bull case:<\/strong> Rs 600 | <strong>Bear case:<\/strong> Rs 330<\/li>\n<li><strong>Ticker:<\/strong> COHANCE | <strong>Sector:<\/strong> Pharmaceutical CDMO and Contract Manufacturing | <strong>MCap:<\/strong> Rs 4,140 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 286 to Rs 680 | <strong>PE:<\/strong> 30x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Cohance_Lifesciences_Company_Overview\"><\/span><strong>Cohance Lifesciences Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cohance Lifesciences (NSE: COHANCE) is a Hyderabad-based pharmaceutical CDMO and formerly Suven Life Sciences&#8217; CDMO arm, manufacturing APIs and intermediates for global pharmaceutical companies under long-term manufacturing agreements. At CMP Rs 414 against a 52 week range of Rs 286 to Rs 680, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 4,140 crore with trailing PE of 30x. Compared to peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences, Cohance Lifesciences is positioned as a potential re-rating candidate toward the Rs 495 price objective on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>COHANCE<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceutical CDMO and Contract Manufacturing<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 414<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 680<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 286<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 4,140 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>30x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 495<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 600<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 330<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">Top Stock Picks<\/a> now on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Cohance_Lifesciences_Share_Price_Target_Set_at_Rs_495_for_2026\"><\/span><strong>Why Is the Cohance Lifesciences Share Price Target Set at Rs 495 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Cohance Lifesciences share price target<\/strong> of Rs 495 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 495 price objective represents the base case with FY27 execution as the key variable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Pharmaceutical_CDMO_and_Contract_Manufacturing\"><\/span><strong>Structural Sector Tailwinds in Pharmaceutical CDMO and Contract Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceutical CDMO and Contract Manufacturing sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Cohance Lifesciences&#8217;s position among peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 600 bull case to materialise.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Cohance Lifesciences&#8217;s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 495 analyst consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Cohance Lifesciences&#8217;s Pharmaceutical CDMO and Contract Manufacturing operations, improving the probability of achieving the Rs 495 price objective through FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 30x PE, Cohance Lifesciences is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 600 bull case over the medium term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cohance_Lifesciences_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Cohance Lifesciences Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Cohance_Lifesciences_Share_Price_Target\"><\/span><strong>Short Term Cohance Lifesciences Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for Cohance Lifesciences is anchored close to the 52 week low of Rs 286. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Cohance_Lifesciences_Share_Price_Target_2026\"><\/span><strong>12-Month Cohance Lifesciences Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Cohance Lifesciences share price target 2026<\/strong> is Rs 495, implying approximately 20 percent upside from CMP Rs 414. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker COHANCE.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Cohance_Lifesciences_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Cohance Lifesciences Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term Cohance Lifesciences share price target<\/strong> for FY27 to FY28 is Rs 600 in the bull case, requiring full earnings delivery, re-rating among peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences, and sustained institutional buying over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_Cohance_Lifesciences_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for Cohance Lifesciences in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Cohance_Lifesciences_Share_Price_Target_Rs_600\"><\/span><strong>Bull Case Cohance Lifesciences Share Price Target: Rs 600<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case Cohance Lifesciences share price target<\/strong> of Rs 600 materialises when FY27 earnings beat analyst estimates, Pharmaceutical CDMO and Contract Manufacturing tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 414, this represents approximately 45 percent potential upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Cohance_Lifesciences_Share_Price_Target_Rs_330\"><\/span><strong>Bear Case Cohance Lifesciences Share Price Target: Rs 330<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case Cohance Lifesciences share price target<\/strong> of Rs 330 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 286.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 600<\/td>\n<td>FY27 beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 495<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 330<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_Cohance_Lifesciences_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the Cohance Lifesciences 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the <strong>Cohance Lifesciences share price target<\/strong> of Rs 495, with FII outflows being the direct transmission mechanism to Indian equity valuations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 495 analyst price objective. Investors must monitor quarterly results and management commentary closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_Pharmaceutical_CDMO_and_Contract_Manufacturing_Peers\"><\/span><strong>Competitive Intensity Among Pharmaceutical CDMO and Contract Manufacturing Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences could compress Cohance Lifesciences&#8217;s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 495 analyst target for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Cohance_Lifesciences\"><\/span><strong>How to Invest in Cohance Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>Cohance Lifesciences share price target<\/strong> of Rs 495, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical CDMO and Contract Manufacturing sector demand.<\/p>\n<p>Open a Demat account with a SEBI registered stockbroker to trade Cohance Lifesciences (NSE: COHANCE) with regulatory protection. Study the competitive landscape among peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences before executing any position.<\/p>\n<p>Plan your entry using the 52 week low of Rs 286 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 495 price objective. Always set a stop loss below the 52 week low.<\/p>\n<p>Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Cohance Lifesciences&#8217;s live share price and receive daily stock recommendations.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Cohance_Lifesciences_Share_Price_Target_2026\"><\/span><strong>FAQs on Cohance Lifesciences Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Cohance_Lifesciences_share_price_target_for_2026\"><\/span><strong>What is the Cohance Lifesciences share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Cohance Lifesciences share price target 2026 is Rs 495, implying approximately 20 percent upside from CMP Rs 414. Bull case is Rs 600, bear case is Rs 330.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Cohance_Lifesciences_share_price_target_for_2025\"><\/span><strong>What was the Cohance Lifesciences share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price objective for Cohance Lifesciences was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 495, reflecting FY27 growth potential from CMP Rs 414.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Cohance_Lifesciences_a_good_investment_at_Rs_414\"><\/span><strong>Is Cohance Lifesciences a good investment at Rs 414?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 414, Cohance Lifesciences offers potential upside toward Rs 495 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Cohance_Lifesciences_share_price_target_2026\"><\/span><strong>What are the key risks to the Cohance Lifesciences share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Cohance Lifesciences share price target of Rs 495 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical CDMO and Contract Manufacturing. Monitoring quarterly results is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Cohance_Lifesciences\"><\/span><strong>What is the 52 week high and low of Cohance Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Cohance Lifesciences is Rs 680 and the 52 week low is Rs 286. At CMP Rs 414, the stock is below its 52 week high and offers potential upside toward the Rs 495 price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_Cohance_Lifesciences_in_2026\"><\/span><strong>What are the main growth catalysts for Cohance Lifesciences in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key catalysts include FY27 PAT recovery, Pharmaceutical CDMO and Contract Manufacturing sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Cohance_Lifesciences_compare_to_its_peers\"><\/span><strong>How does Cohance Lifesciences compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cohance Lifesciences operates in Pharmaceutical CDMO and Contract Manufacturing alongside peers in pharma CDMO like Divi&#8217;s Laboratories and Anthem Biosciences. At CMP Rs 414 with MCap Rs 4,140 crore, it is a potential re-rating candidate toward the Cohance Lifesciences share price target of Rs 495 on FY27 delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Cohance_Lifesciences_share_price_target_for_2027\"><\/span><strong>What is the Cohance Lifesciences share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Cohance Lifesciences share price target for FY27 to FY28 is Rs 600 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Cohance Lifesciences share price target 2026 is Rs 495, ~20% upside from CMP Rs 414. Bull Rs 600, bear Rs 330. 2026.<\/p>\n","protected":false},"author":35,"featured_media":125796,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-123743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782117447:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Cohance Lifesciences Share Price Target 2026: Rs 495 Analyst Forecast"],"rank_math_description":["The Cohance Lifesciences share price target 2026 is Rs 495, ~20% upside from CMP Rs 414. Bull Rs 600, bear Rs 330. 2026."],"rank_math_focus_keyword":["Cohance Lifesciences share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["125796"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["19915"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Cohance-Lifesciences-Share-Price-Target-2026-Analyst-Forecast-Bull-and-Bear-Case.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=123743"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123743\/revisions"}],"predecessor-version":[{"id":125797,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/123743\/revisions\/125797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/125796"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=123743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=123743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=123743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}